The stock of Altimmune Inc (ALT) has seen a -1.63% decrease in the past week, with a -6.07% drop in the past month, and a -9.06% decrease in the past quarter. The volatility ratio for the week is 2.93%, and the volatility levels for the past 30 days are at 4.42% for ALT. The simple moving average for the past 20 days is -3.03% for ALT’s stock, with a -17.58% simple moving average for the past 200 days.
Is It Worth Investing in Altimmune Inc (NASDAQ: ALT) Right Now?
The stock has a 36-month beta value of 0.58. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ALT is 80.26M, and at present, short sellers hold a 28.25% of that float. On June 04, 2025, the average trading volume of ALT was 2.53M shares.
ALT) stock’s latest price update
The stock of Altimmune Inc (NASDAQ: ALT) has increased by 2.26 when compared to last closing price of 5.30.Despite this, the company has seen a loss of -1.63% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-02 that I rate Altimmune a ‘Strong Buy’ and Viking Therapeutics a ‘Buy’ for high-risk, long-term investors. ALT’s Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in multiple metabolic diseases, making it an attractive acquisition target. VKTX’s VK2735 offers strong weight loss efficacy and dual formulation flexibility, but faces tough competition and lacks clear differentiation, despite financial stability.
Analysts’ Opinion of ALT
Stifel, on the other hand, stated in their research note that they expect to see ALT reach a price target of $18. The rating they have provided for ALT stocks is “Buy” according to the report published on January 08th, 2025.
UBS gave a rating of “Buy” to ALT, setting the target price at $26 in the report published on November 12th of the previous year.
ALT Trading at 4.78% from the 50-Day Moving Average
After a stumble in the market that brought ALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.43% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALT starting from Sohn Catherine A., who purchase 1,000 shares at the price of $5.78 back on Mar 17 ’25. After this action, Sohn Catherine A. now owns 1,000 shares of Altimmune Inc, valued at $5,784 using the latest closing price.
WEAVER GREGORY L, the Chief Financial Officer of Altimmune Inc, purchase 10,000 shares at $5.20 during a trade that took place back on Mar 13 ’25, which means that WEAVER GREGORY L is holding 10,000 shares at $51,996 based on the most recent closing price.
Stock Fundamentals for ALT
Current profitability levels for the company are sitting at:
- -4909.65 for the present operating margin
- -2.3 for the gross margin
The net margin for Altimmune Inc stands at -4512.0. The total capital return value is set at -0.67. Equity return is now at value -57.28, with -52.22 for asset returns.
Currently, EBITDA for the company is -94.81 million with net debt to EBITDA at 0.53. When we switch over and look at the enterprise to sales, we see a ratio of 19524.8. The receivables turnover for the company is 0.04for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.82.
Conclusion
To sum up, Altimmune Inc (ALT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
